X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
CITI-002 (lidocaine-halobetasol propionate) is a proprietary topical formulation intended to provide symptomatic relief to individuals suffering from hemorrhoids, a gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding.
Lead Product(s): Lidocaine,Halobetasol
Therapeutic Area: Gastroenterology Product Name: CITI-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
CITI-002 (lidocaine-halobetasol propionate) is a proprietary topical formulation intended to provide symptomatic relief to individuals suffering from hemorrhoids, a gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding.
Lead Product(s): Lidocaine,Halobetasol
Therapeutic Area: Gastroenterology Product Name: CITI-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Halo-Lido is a proprietary topical formulation of halobetasol and lidocaine that is intended to provide symptomatic relief to individuals suffering from hemorrhoids, a gastrointestinal disorder.
Lead Product(s): Halobetasol,Lidocaine
Therapeutic Area: Gastroenterology Product Name: Halo-Lido
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
The presentations will feature new efficacy and safety analyses of ARAZLO® (tazarotene) Lotion, 0.045%, long-term outcomes of DUOBRII® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, quality of life improvement with SILIQ® (brodalumab) injection.
Lead Product(s): Halobetasol,Tazarotene
Therapeutic Area: Dermatology Product Name: Duobrii
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
When administered together in DUOBRII, they provide complementary effects due to their individual modes of action targeting different receptors and pathways to achieve anti-inflammatory control and epidermal morphologic restoration.
Lead Product(s): Halobetasol,Tazarotene
Therapeutic Area: Dermatology Product Name: Duobrii
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
